Alnylam Pharmaceuticals at TIDES Europe 2026
Nov 3–5, 2026 Amsterdam, Netherlands ~900 attendees Website
Alnylam Pharmaceuticals takes part in 2 sessions at TIDES Europe 2026 in Amsterdam. Its sessions cover RNAi therapeutics from target choice to manufacturing. It reports pipeline progress on genetically validated targets for the next wave of RNAi medicines, and with Almac describes siRELIS, a convergent enzymatic ligation strategy for making siRNA.
| Organization | TIDES Europe 2026 Attendance |
|---|---|
Alnylam Pharmaceuticals Cambridge, MA | |
Develops and markets RNA interference (RNAi) therapeutics, including GalNAc-conjugated siRNA medicines for genetic, cardiometabolic and other diseases. | Talk Thu Nov 5 15:00–15:30 Genetically Validated Targets and the Next Wave of RNAi Therapeutics: Progress from the Alnylam Pipeline Progress in gene-silencing medicines at one company, including how human genetics points to new targets and what a broad pipeline has taught them. Talk Thu Nov 5 10:45–11:25 Part 1: siRELIS: A Convergent Enzymatic Ligation Strategy for siRNA Manufacturing; Part 2: Enzyme Development for Oligonucleotide Therapeutics Manufacturing Using engineered joining enzymes to assemble siRNA from short building blocks, and what scaling that approach taught two companies. |
Instantly find 20 buyers from Alnylam Pharmaceuticals
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by Informa Connect or TIDES Europe. Submit a correction